GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Capex-to-Operating-Income

Alto Neuroscience (Alto Neuroscience) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Alto Neuroscience's Capital Expenditure for the three months ended in Mar. 2024 was $-0.22 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-14.39 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Alto Neuroscience Capex-to-Operating-Income Historical Data

The historical data trend for Alto Neuroscience's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Capex-to-Operating-Income Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23
Capex-to-Operating-Income
- - -

Alto Neuroscience Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial - - - - -

Competitive Comparison of Alto Neuroscience's Capex-to-Operating-Income

For the Biotechnology subindustry, Alto Neuroscience's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alto Neuroscience's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's Capex-to-Operating-Income falls into.



Alto Neuroscience Capex-to-Operating-Income Calculation

Alto Neuroscience's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.47) / -37.809
=N/A

Alto Neuroscience's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.224) / -14.386
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alto Neuroscience  (NYSE:ANRO) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Alto Neuroscience Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Alto Neuroscience (Alto Neuroscience) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus